Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Future of the lymphoma field

Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving treatment landscape of lymphoma, including recent data evaluating allogeneic CAR T-cells in the relapsed/refractory setting. Furthermore, the development of novel targeted agents such as tafasitamb, as evaluated in the Phase II L-MIND study (NCT02399085), represents an exciting approach in the lymphoma field. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).